Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on August 15

Rhea-AI Summary

Genetic Technologies (NASDAQ:GENE) is hosting an exclusive live investor webinar and Q&A session on August 15, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature senior executives discussing the company's genomics-based test portfolio for health, wellness, and serious diseases. Key highlights include:

- EasyDNA platform with over $7 million in annual recurring revenues
- Expanding product portfolio with 50+ risk assessment tests in 14 categories
- 25 granted patents and 9 pending
- B2B commercialization strategy for geneType multi-risk test
- Expanding direct-to-consumer testing programs
- Global predictive genomics market expected to reach $4.6 billion by 2025 (17%+ CAGR)
- Recent corporate restructure to reduce cash burn and focus on sales

Positive

• EasyDNA platform generates over $7 million in annual recurring revenues
• Expanding product portfolio with more than 50 risk assessment tests in 14 categories
• 25 patents granted and 9 patents pending
• Global predictive genomics market expected to reach $4.6 billion by 2025, growing at 17%+ CAGR
• Recent corporate restructure has reduced cash burn to focus on sales and commercialization

Negative

• None.

MELBOURNE, Australia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on August 15, 2024, at 4:15 p.m. ET.

The exclusive event, hosted by RedChip Companies, will feature some of Genetic Technologies Senior Executives, who will share insight into the Company’s portfolio of genomics-based tests targeting health, wellness and serious disease.

Genetic Technologies’ EasyDNA platform has over $7m in annual recurring revenues in the Paternity and Health and wellness space across global markets along with its expanding product portfolio including more than 50 risk assessment tests in 14 test categories covered by 25 patents granted and nine patents pending. In addition to its B2B commercialization strategy for its flagship geneType multi-risk test, Genetic Technologies is also focused on expanding its direct-to-consumer testing programs.

The global market for predictive genomics is expected to reach $4.6 billion by 2025, growing at a CAGR of 17%+. A recent corporate restructure has dramatically reduced cash burn to allow the company to focus on sales and commercialization of its world leading technology.

To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_2FW_eKhRRVOle8Lq96GWog#/registration

Questions can be pre-submitted to GENE@redchip.com or online during the live event.

About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness, and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com.

Forward-Looking Statements
This press release may contain forward-looking statements about the Company’s expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company’s filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
GENE@redchip.com

FAQ

When is Genetic Technologies (GENE) hosting its live investor webinar?

Genetic Technologies (GENE) is hosting its live investor webinar on August 15, 2024, at 4:15 p.m. ET.

What is the annual recurring revenue of Genetic Technologies' (GENE) EasyDNA platform?

Genetic Technologies' (GENE) EasyDNA platform has over $7 million in annual recurring revenues in the Paternity and Health and wellness space across global markets.

How many risk assessment tests does Genetic Technologies (GENE) offer?

Genetic Technologies (GENE) offers more than 50 risk assessment tests across 14 test categories.

What is the projected market size for predictive genomics by 2025?

The global market for predictive genomics is expected to reach $4.6 billion by 2025, growing at a CAGR of over 17%.